|
Aqueous Formulations of Cytotoxic Taxanes with Cyclodextrin
NU 2022-109
INVENTORS
Brittney Williams
Matthew Thompson
Nathan Gianneschi*
SHORT DESCRIPTION
This invention describes aqueous formulations of cytotoxic taxane drugs conjugated to fatty acids, solubilized using cyclodextrin inclusion complexes, providing water-soluble chemotherapy formulations that eliminate the need for toxic organic solvents...
Published: 2/25/2026
|
Inventor(s):
Keywords(s):
Category(s): Life Sciences > Therapeutics
|
|
Methods of Using Modified Cytotoxins to Treat Cancer
NU 2019-135
INVENTORS
Nathan Gianneschi*
SHORT DESCRIPTION
Methods for treating cancers that overexpress fatty acid uptake proteins using small-molecule cytotoxic drugs conjugated to long-chain fatty acid moieties. See also NU2022-111.
BACKGROUND
While prior work (under NU2022-111) demonstrated that lipid-mimicking cytotoxin prodrugs with fatty...
Published: 2/25/2026
|
Inventor(s):
Keywords(s): Cancer/Oncology, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Modified Cytotoxins and their Therapeutic Use
NU 2022-111
INVENTORS
Cassandra Callmann
Matthew Thompson
Clare LeGuyader
Paul Bertin
Nathan Gianneschi*
SHORT DESCRIPTION
This invention is for chemically modified small-molecule cytotoxic drugs conjugated to long-chain fatty acid-like hydrophobic moieties that bind non-covalently to albumin, creating improved cancer therapeutics with enhanced...
Published: 2/25/2026
|
Inventor(s):
Keywords(s):
Category(s): Life Sciences > Therapeutics
|
|
Cooperative Catalysis System for Enantioselective Transformations of Oxocarbenium Ions
NU 2019-063
INVENTORS
Karl Scheidt*
Mark Andrew Maskeri
SHORT DESCRIPTION
This invention introduces a cooperative catalysis system that enhances the reactivity and selectivity of oxocarbenium ions, facilitating new enantioselective transformations and enabling the synthesis of pharmacologically active tetrahydropyranoindole compounds.
BACKGROUND...
Published: 2/24/2026
|
Inventor(s):
Keywords(s):
Category(s): Life Sciences > Therapeutics
|
|
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION
Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy.
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
Jindan...
Published: 2/24/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Novel Serotonin Receptor Agonist to Treat Neurological Disease
NU 2018-135
INVENTORS
Karl Scheidt*
Adam Csakai
Herbert Meltzer
SHORT DESCRIPTION
A novel small molecule that selectively targets serotonin 5-HT2c receptors for the treatment of psychiatric, mental, and/or neurological diseases.
BACKGROUND
Serotonin is a neurotransmitter known to regulate a variety of neurological functions, and alterations in...
Published: 2/24/2026
|
Inventor(s):
Keywords(s): Neurodegenerative disease, Neurologic disease, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Method for the synthesis of heteroyohimbine natural products
NU 2015-009
INVENTORS
Karl Scheidt*
Herbert Meltzer
Ashkaan Younai
Bi-Shun Zeng
SHORT DESCRIPTION
Enantioselective synthetic methods for preparing heteroyohimbine alkaloid intermediates using a novel cooperative hydrogen bonding/enamine-catalyzed Michael addition reaction as a key step to access complex natural products, including alstonine...
Published: 2/24/2026
|
Inventor(s):
Keywords(s): Drug discovery, Neurologic disease, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Netrin-1 mimetic peptide amphiphiles
Netrin-1 Mimetic Peptide Amphiphile Assemblies
NU 2024-174
INVENTORS
Samuel Stupp*
Cara Smith
Zaida Alvarez Pinto
SHORT DESCRIPTION
Nanofiber-shaped supramolecular assemblies that mimic netrin-1 bioactivity to stimulate neurite growth and synaptic maturation for enhanced CNS regeneration.
BACKGROUND
Neurotrophic factors are essential for...
Published: 2/20/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, CNS - Central Nervous System, CVA - Cerebrovascular Accident, Nanomaterials, Nanotechnology, Neurodegenerative disease, Regenerative medicine, SCI - Spinal cord injury, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Targeting IL-6 pathway to treat high risk myelodysplastic syndromes
NU 2022-093
INVENTORS
Peng Ji*
Kehan Ren
Yang Mei
SHORT DESCRIPTION
A method of inhibiting progression of high-risk myelodysplastic syndrome (MDS) or low blast count acute myeloid leukemia (AML) using an inhibitor of IL6 signaling.
BACKGROUND
Approximately 20,000 people in the US are diagnosed with myelodysplastic syndrome (MDS) each year....
Published: 2/17/2026
|
Inventor(s):
Keywords(s): AML - Acute myeloid leukemia, Repurposed Drugs, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Retinoic Acid Agonists for Attenuation of Doxorubicin-Induced Cardiotoxicity
SHORT DESCRIPTION
A method for preventing cardiotoxicity in patients undergoing anthracycline-based chemotherapy using retinoic acid receptor gamma (RARG) agonists.
INVENTORS
Paul W Burridge*, PhD
Associate Professor, Pharmacology, Northwestern University Feinberg School of Medicine
* Principal Investigator
NU...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): Cancer Treatment, Cancer/Oncology, Cardiology and Cardiovascular disease, Chemotherapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|